CD19-specific CAR T cell therapy for the treatment of CD19-positive B cell malignancies such as B-cell acute lymphoblastic leukemia (B-ALL), B-cell non-Hodgkin lymphoma (NHL), or chronic lymphocytic leukemia (CLL) has had remarkable success (5–8), resulting in their recent US Food and Drug Administration (FDA) approval. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.